دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The far-reaching beneficial effects of sodium–glucose co-transporter 2 inhibitors in heart failure
Filippo Crea
doi : 10.1093/eurheartj/ehac437
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Pages 2907–2910
What cardiologists should know about sleepÂ
Martino Francesco Pengo, Sogol Javaheri, Manuel Sanchez-de-la-Torre, Esther Irene Schwarz
doi : 10.1093/eurheartj/ehac349
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Pages 2911–2913
Frankfurt scientists lead the way with funding for three visionary research projectsÂ
Judith Ozkan
doi : 10.1093/eurheartj/ehac316
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Pages 2914–2915
A multinational European network to implement integrated care in elderly multimorbid atrial fibrillation patients: the AFFIRMO ConsortiumÂ
Søren P Johnsen, Marco Proietti, Aldo P Maggioni, Gregory Y H Lip
doi : 10.1093/eurheartj/ehac265
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Pages 2916–2918
The UK TAVI trial: an independent, pragmatic study extending the evidence for the treatment of symptomatic severe aortic stenosisÂ
Rocco Vergallo, Massimo Volpe
doi : 10.1093/eurheartj/ehac345
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Pages 2919–2920
Critical appraisal of artificial intelligence-based prediction models for cardiovascular diseaseÂ
Maarten van Smeden, Georg Heinze, Ben Van Calster, Folkert W Asselbergs, Panos E Vardas, Nico Bruining, Peter de Jaegere, Jason H Moore, Spiros Denaxas, Anne Laure Boulesteix, Karel G M Moons
doi : 10.1093/eurheartj/ehac238
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Pages 2921–2930
The medical field has seen a rapid increase in the development of artificial intelligence (AI)-based prediction models. With the introduction of such AI-based prediction model tools and software in cardiovascular patient care, the cardiovascular researcher and healthcare professional are challenged to understand the opportunities as well as the limitations of the AI-based predictions.
Non-steroidal mineralocorticoid receptor antagonists in cardiorenal diseaseÂ
Arjun K Pandey, Deepak L Bhatt, Francesco Cosentino, Nikolaus Marx, Ori Rotstein, Bertram Pitt, Ambarish Pandey, Javed Butler, Subodh Verma
doi : 10.1093/eurheartj/ehac299
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Pages 2931–2945
Despite existing treatments, patients with heart failure and chronic kidney disease (CKD) remain at high risk for adverse outcomes and progression to end-stage disease. Steroidal mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone reduce mortality but remain under-prescribed due to the perceived risk of hyperkalaemia and hormonal side effects.
Anti-interleukin-1 agents for pericarditis: a primer for cardiologistsÂ
Massimo Imazio, George Lazaros, Marco Gattorno, Martin LeWinter, Antonio Abbate, Antonio Brucato, Allan Klein
doi : 10.1093/eurheartj/ehab452
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Pages 2946–2957
Anti-interleukin (IL)-1 agents have been developed for the treatment of autoinflammatory and rheumatic conditions, where overproduction of IL-1 is an important pathophysiologic process.
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trialÂ
Kazuma Oyama, Itamar Raz, Avivit Cahn, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Kyong Soo Park, Assen Goudev, Rafael Diaz, Jindřich Špinar, Ingrid A M Gause-Nilsson, Ofri Mosenzon, Marc S Sabatine, Stephen D Wiviott
doi : 10.1093/eurheartj/ehab530
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Pages 2958–2967
We investigated the associations between obesity, cardiorenal events, and benefits of dapagliflozin in patients with type 2 diabetes mellitus (T2DM).
Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insightsÂ
Naveed Sattar, Stefan D Anker, Javed Butler, Subodh Verma
doi : 10.1093/eurheartj/ehab709
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Pages 2968–2970
Post-operative atrial fibrillation and risk of heart failure hospitalizationÂ
Parag Goyal, Michael Kim, Udhay Krishnan, Stephen A Mccullough, Jim W Cheung, Luke K Kim, Ambarish Pandey, Barry A Borlaug, Evelyn M Horn, Monika M Safford, Hooman Kamel
doi : 10.1093/eurheartj/ehac285
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Pages 2971–2980
Post-operative atrial fibrillation (POAF) is associated with stroke and mortality. It is unknown if POAF is associated with subsequent heart failure (HF) hospitalization. This study aims to examine the association between POAF and incident HF hospitalization among patients undergoing cardiac and non-cardiac surgeries.
Post-operative AF and heart failure hospitalizations: what remains hidden in patients undergoing surgery Â
Melissa E Middeldorp, Christine M Albert
doi : 10.1093/eurheartj/ehac335
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Pages 2981–2983
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-PooledÂ
João Pedro Ferreira, Faiez Zannad, Javed Butler, Gerasimos Filipattos, Ivana Ritter, Elke Schüler, Bettina J Kraus, Stuart J Pocock, Stefan D Anker, Milton Packer
doi : 10.1093/eurheartj/ehac306
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Pages 2984–2993
Hyperkalaemia frequently leads to interruption and discontinuation of neurohormonal antagonists, which may worsen heart failure prognosis. Some studies suggested that sodium-glucose cotransporter 2 inhibitors reduce hyperkalaemia, an effect that may have important clinical implications. This analysis evaluates the effect of empagliflozin on the occurrence of hyper- and hypokalaemia in HF.
Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failureÂ
Subodh Verma, Nitish K Dhingra, Arjun K Pandey, Francesco Cosentino
doi : 10.1093/eurheartj/ehac304
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Pages 2994–2996
The sounds of silenceÂ
Alessandro Parolari, Rui M S Almeida, William E Boden,
doi : 10.1093/eurheartj/ehac333
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Page 2997,
Left main revascularization: breaking through the sounds of silenceÂ
Mario Gaudino, Michael E Farkouh, Gregg W Stone
doi : 10.1093/eurheartj/ehac340
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Page 2998
Paroxysmal massive mitral regurgitation
Xin Wei, Minggang Zhou, Yong Chen, Mao Chen
doi : 10.1093/eurheartj/ehac318
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Page 2999
Popeye’s sign and transthyretin amyloidosis
Nobuhiro Tahara, Akihiro Honda, Mitsuharu Ueda, Yoshihiro Fukumoto
doi : 10.1093/eurheartj/ehac330
European Heart Journal, Volume 43, Issue 31, 14 August 2022, Page 3000
